Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAd-p53 Gene Therapy with TAE in Advanced HCC
NCT02509169Phase 2Unknown
- Sponsor
- Shenzhen SiBiono GeneTech
- Start
- Oct 2014
- Primary completion
- Dec 2016
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of rAdp53 in hepatocellular carcinoma (HCC), sponsored by Shenzhen SiBiono GeneTech. Status: unknown.
02
Drugs
rAdp53
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02509169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509169.